Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIAN-SHAN7: Phase I/II study of DZD6008 combination therapy in EGFR-mutant advanced non-small cell lung cancer
CTR20252134Phase 2Active
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DZD6008 in non-small cell lung cancer (NSCLC), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Jul 2025; status: active.
02
Drugs
DZD6008
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20252134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252134.